

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)



(10) International Publication Number
WO 2025/038800 A1

(51) International Patent Classification:
C07K 14/005 (2006.01) A61K 48/00 (2006.01)
C12N 15/86 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/042405

Published:
— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
15 August 2024 (15.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/519,952 16 August 2023 (16.08.2023) US

(71) Applicant: **VOYAGER THERAPEUTICS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **NONNENMACHER, Mathieu Emmanuel**; c/
o Voyager Therapeutics, Inc., 75 Hayden Avenue, Lex-
ington, Massachusetts 02421 (US). **REN, Amy Zhen**; 53
Brookdale Rd., Newton, Massachusetts 02460 (US). **MAU-
RA, Damien**; c/o Voyager Therapeutics, Inc., 75 Hayden
Avenue, Lexington, Massachusetts 02421 (US). **WANG,
Wei**; 5 Meadow Brook Avenue, Lexington, Massachusetts
02421 (US).

(74) Agent: **TRIDICO, Anthony**; Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP, 901 New York Avenue,
NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO FRATAXIN DEFICIEN-
CY

(57) Abstract: The disclosure relates to compositions and methods for altering, e.g., enhancing, the level of frataxin protein via delivery
using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment
of subjects who have, have been diagnosed with having, or are at risk of having a disorder associated with frataxin (FXN) deficiency,
e.g., Friedreich's Ataxia.

WO 2025/038800 A1